Medical Educational Resource
Pfizer’s investigational gene therapy (PF-06939926) for Duchenne muscular dystrophy
This program is sponsored by Pfizer. This program is not sponsored, endorsed, or accredited by MDA.
In this webinar, Beth Belluscio, Pfizer Global Clinical Lead for Rare Neurological Disorders, will discuss the Phase 3 study of PF-06939926, a gene therapy for Duchenne muscular dystrophy. Beth will answer questions about the study including aspects of the design and the criteria for enrollment.